Symic Bio
953 Indiana Street
San Francisco
California
94107
United States
Tel: 415-805-9005
Website: http://www.symic.bio/
Email: info@symic.bio
35 articles about Symic Bio
-
Symic Bio Announces Closing of Investment led by CIP
4/25/2019
Existing investors also participated in the financing, bringing the total raised as part of these financings to $11 million.
-
Symic Bio Selected for "The Best of The Liver Meeting 2018" at AASLD
11/9/2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that they were selected for "The Best of The Liver Meeting 2018" at the AASLD international liver meeting and will be presenting on its liver fibrosis program at the upcoming conference in San Francisco.
-
Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director
7/31/2018
Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the oncology field announces today the appointment of Barbara Yanni to its Board of Directors as an Independent Director.
-
Symic Bio to Present at the 10th Annual ChinaBio Partnering Forum
4/18/2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Rinko Ghosh, President and Chief Business Officer, will present an overview of the company pipeline at the 10th Annual ChinaBio Partnering Forum being held April 25-26, 2018, in Suzhou, China.
-
Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
4/2/2018
- Data from 12-month follow-up demonstrates statistically significant improvement in clinical efficacy outcome - - Trial of SB-030 in prevention of vein graft failure in patients with advanced peripheral vascular disease planned to begin in the second half of 2018 -
-
Symic Bio to Present at the BioCentury 25th Annual Future Leaders Conference in New York
3/15/2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the BioCentury 25th Annual Future Leaders in the Biotech Industry Conference in New York.
-
Symic Bio Announces Results of Locally-Administered Therapeutic SB-030 in Preclinical Model of Vascular Intervention
3/5/2018
Symic Bio announced results from a preclinical study of locally-applied therapeutic SB-030 in the reduction of inflammatory response and clot formation.
-
Symic Bio Completes the MODIFY2 Phase II Trial of SB-061 for the Treatment of Knee Osteoarthritis
2/7/2018
The 12-week, multicenter, double-blind trial of 60 patients was designed to investigate the effects of SB-061 in the overall population as well as a prespecified subpopulation of patients with knee effusions.
-
Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior VP of Discovery Biology
1/22/2018
With this appointment, Dr. Alaoui will lead research into the identification and characterization of novel therapeutics enabled by the Symic Bio platform.
-
Symic Bio Appoints Wayne Froland, Ph.D., as Executive VP of Technical Operations
11/3/2017
Dr. Froland has over 20 years of experience in industry primarily focusing on process development in biopharma manufacturing.
-
Symic Bio Announces Results From the Phase I//I SHIELD Trial of SB-030 in Peripheral Vascular Disease
11/1/2017
In a first-in-human, prospective, randomized, single-blind controlled study of 67 patients, SB-030 demonstrated a positive safety profile, with no clinically meaningful difference observed in adverse events between treatment and control groups.
-
Symic Biomedical Enrolls First Patient In MODIFY2 Phase II Trial Of SB-061 For The Treatment Of Osteoarthritis
8/23/2017
-
Symic Biomedical Appoints Matrix Biology Researcher And Professor Glenn Prestwich As Executive Vice President Of Chemistry
7/5/2017
-
Bay Area's Symic Biomedical Locks In $30 Million Series B
5/23/2017
-
Symic Biomedical Announces Results From MODIFY-OA Trial Of SB-061 For The Treatment Of Osteoarthritis Of The Knee
5/18/2017
-
Symic Biomedical Announces Last Patient Enrolled In SHIELD Trial Of SB-030 For Interventions In Peripheral Artery Disease
2/24/2017
-
Symic Biomedical Appoints Scott W. Morrison To Board Of Directors
1/30/2017
-
Symic Biomedical And Nordic Bioscience A/S Complete Enrollment Of MODIFY-OA Trial Of SB-061 For The Treatment Of Osteoarthritis
11/11/2016
-
Symic Biomedical Appoints Morten Karsdal, Ph.D., To Scientific Advisory Board
10/19/2016
-
Symic Biomedical To Present At The 15th Annual BIO Investor Forum
10/11/2016